Provided by Tiger Trade Technology Pte. Ltd.

Regeneron Pharmaceuticals

774.11
-19.6300-2.47%
Post-market: 775.641.53+0.20%19:55 EDT
Volume:540.84K
Turnover:419.72M
Market Cap:79.70B
PE:19.15
High:788.58
Open:788.53
Low:769.57
Close:793.74
52wk High:859.34
52wk Low:541.00
Shares:102.95M
Float Shares:98.88M
Volume Ratio:0.99
T/O Rate:0.55%
Dividend:3.64
Dividend Rate:0.47%
EPS(TTM):40.43
EPS(LYR):41.48
ROE:14.04%
ROA:6.53%
PB:2.51
PE(LYR):18.66

Loading ...

Sep 04, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Sep 03, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Sep 03, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Aug 10, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Aug 10, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jul 30, 2026

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Jul 30, 2026

Major Issues Report

Form 8-K - Current report
Jul 06, 2026

Major Issues Report

Form 8-K - Current report
Jul 02, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jun 18, 2026

Major Issues Report

Form 8-K - Current report
Apr 30, 2026

Beneficial Ownership Change

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
Apr 29, 2026

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Apr 29, 2026

Major Issues Report

Form 8-K - Current report
Apr 08, 2026

Major Issues Report

Form 8-K - Current report
Feb 19, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Feb 09, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Feb 09, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Feb 04, 2026

Annual Report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Jan 30, 2026

Major Issues Report

Form 8-K - Current report
Jan 12, 2026

Major Issues Report

Form 8-K - Current report